Logo

Merck's Keytruda (pembrolizumab) Receives the US FDA's Priority Review for the Adjuvant Treatment of Stage II Resected High-Risk Melanoma

Share this

Merck's Keytruda (pembrolizumab) Receives the US FDA's Priority Review for the Adjuvant Treatment of Stage II Resected High-Risk Melanoma

Shots:

  • The priority review is based on P-III KEYNOTE-716 trial assessing Keytruda (anti-PD-1 therapy) vs PBO in 954 patients aged ≥12yrs. with stage II resected high-risk melanoma. The anticipated PDUFA date for the therapy is Dec 04- 2021
  • The trial met its 1EPs of RFS with no new safety signals observed. Based on this data- the US FDA has accepted a new sBLA for Keytruda as the adjuvant treatment of adult & pediatric aged≥12yrs. patients with stage IIB or IIC melanoma following complete resection
  • The company has an expansive program to evaluate the therapy in early disease states with ongoing ~20 registrational studies

Ref: Merck | Image: Merck

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions